Cotinga Pharmaceuticals Inc COTQF

Healthcare Biotechnology

Cotinga Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's lead clinical candidate, COTI-2, is an oral small molecule targeting p53, a tumor suppressor gene that is mutated in over 50% of all cancers, and the company's second clinical candidate, COTI-219, is a novel oral small molecule compound targeting the mutant forms of KRAS with such mutations occurring in up to 30% of all cancers.

GREY:COTQF - Post by User

Cotinga Pharmaceuticals Inc > Extremely undervalued for what we have .....

<< Previous

Bullboard Posts

Next >>

Comment by DIYGuyon Jan 06, 2018 12:43pm

93 Views

Post# 27297245

RE:Extremely undervalued for what we have .....

Shinseki? Really? Read my posts again. Never been a fan of spending so much money on IR when we need the cash for clinical trials.

I agree somewhat on valuation. However, burning through so much cash and needing more leaves them desperate. Until we have more positive news and multiple people or partners are lining up them we are at the mercy of the capital market. They will take as much as they can get for the cheapest price.

What blows me away was the dump of 9000 shares for 97 cents at the open on Thursday. Who gives their shares away like that, especially after tax loss season had ended.

<< Previous

Bullboard Posts

Next >>

Sirios Resource discovers visible gold in Quebec